Korea Institute of Science and Technology

Korea Research Institute of Chemical Technology

University of California

Hyunah Choo

Yong Seo Cho

Ae Nim Pae

Seon Hee Seo

Kyung Il Choi

Hyewhon Rhim

Jae Kyun Lee

Joo Hwan Cha

Youngjae Kim

Hun Yeong Koh

Gyo Chang Keum

Woo-Kyu Park

Ghilsoo Nam

Youngsoo Kim

Dong Jin Kim

Sang Hee Kim

Sang Eun Chae

Jae Yang Kong

Hee Sup Shin

Eun Joo Roh

Yong Koo Kang

Hee-Yoon Lee

Gildon Choi

Heeyeong Cho

Kye Jung Shin

Eunice Eun-Kyeong Kim

Key-Sun Kim

Hesson Chung

Dong Yun Shin

Hoh Gyu Hahn

Hye Jin Chung

Kee Dal Nam

Yoon Jee Kim

Woong Seo Park

Hye Ran Kim

Mi Young Yeom

Daeyoung Jeong

Kee Hyun Choi

Chan Seong Cheong

Karl Y Hostetler

Hyun Joo Lee

James R Beadle

Young-jae Kim

Hoon Ryu

Sang Deuk Lee

Yun Kyung Kim

Soon Bang Kang

ChangJoon Justin Lee

Daesoo Kim

Ghil Soo Nam

Sun Joon Min

Chi Man Song

You Seung Kim

Jieon Lee

Jee Yeon Kim

Younghee Kim

Soon Hyeok Hong

Jihye Seong

Ji Yoon Kim

Jeeyeon Kim

Yu Jin Hwang

Cheolju Lee

Sun-Joon Min

Tran Huyen Dang

Sungsu Lim

Dabon Lee

Jihoon Jang

Seonmi Jo

Boeun Yoon

Juhyeon Kim

Yoo Ran Ki

Min Joo Kim

Sora Kim

Hyemyung Seo

Vani Nelamane Devegowda

Hwa-Sil Kim

Satish N Chavre

You Na Oh

Ahmed Asif

Seungmi Yeo

Azepine derivatives acting on 5-HTreceptors and pharmaceutically acceptable salts thereof are disclosed. The azepine derivatives and the pharmaceutically acceptable salts thereof have high binding affinities for and high antagonistic activities on 5-HTreceptors. Due to these advantages, the azepine derivatives and the pharmaceutically acceptable salts thereof can be applied to therapeutic or prophylactic agents for central nervous system diseases, such as depression, migraine, anxiety, pain, inflammatory pain, neuropathic pain, body temperature dysregulation, biorhythm dysregulation, sleep disturbance, and smooth muscle diseases where 5-HTreceptors antagonistic activity is required.

Azepine derivatives as 5-HTreceptor modulators

Disclosed is a novel catalyst for producing a methanol precursor. The use of the catalyst enables the production of a methanol precursor and methanol with high efficiency under low temperature and low pressure conditions. Also disclosed are a methanol precursor produced using the catalyst and methanol produced using the methanol precursor.

Catalyst for producing methanol precursor, methanol precursor produced using the catalyst and methanol produced using the methanol precursor

The present disclosure relates to a quinoline derivative which inhibits the activity of histone methyltransferases (ESET/SETDB1) specific for the histone molecule H3K9 or a pharmaceutically acceptable salt thereof and a use thereof.

Quinoline derivatives for inhibiting histone methyltransferases and use thereof

The present invention provides a carbazole derivative represented by Formula 1: wherein X is CHor C(O), Y is selected from NRR, piperidinyl groups in which two of the carbon atoms are substituted with Rand R, piperazinyl groups in which the nitrogen atom is substituted with R, and morpholinyl groups, n is an integer from 2 to 5, Rand R, which may be identical or different, are each independently selected from C-Calkyl, phenyl, and benzyl, with the proviso that Rand Rmay be bonded together to form a ring, Rand R, which may be identical or different, are each independently selected from hydrogen, C-Calkyl, phenyl, and benzyl, and Ris selected from C-Calkyl, C-Calkylcarbonyl, phenyl substituted with C-Calkyloxy, hydroxyphenyl, benzyl, and benzoisoxazol-3-yl; or a pharmaceutically acceptable salt thereof.

Carbazole derivatives acting on 5-HT7 receptor

A pharmaceutical composition for preventing or treating a degenerative brain disease, and a method of screening a material for preventing or treating a degenerative brain disease. The method may effectively screen a prophylactic or therapeutic candidate material for preventing or treating a degenerative brain disease. A variety of degenerative brain diseases may be effectively prevented or treated using the pharmaceutical composition including a screened material for preventing or treating a degenerative brain disease.

Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same

Disclosed are thienopyrimidinone derivatives as antagonists that act on metabotropic glutamate receptor subtype 1. The thienopyrimidinone derivatives show pharmacological activity against metabotropic glutamate receptor-related diseases, including pain, such as neuropathic pain and migraine, psychiatric diseases, such as anxiety disorder and schizophrenia, urinary incontinence, and neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. Also disclosed are methods for preparing the thienopyrimidinone derivatives, and pharmaceutical compositions containing the thienopyrimidinone derivatives as active ingredients.

Thienopyrimidinone derivatives as mGluR1 antagonists

Provided are biphenyl derivatives exhibiting activity towards central nervous system diseases by acting on the 5-HTreceptor, pharmaceutically acceptable salts thereof, a method for preparing the compounds and pharmaceutical compositions including the compounds as an active ingredient.

Biphenyl derivatives, pharmaceutical composition comprising the same, and preparation method thereof

Disclosed are novel imidazolylalkylcarbonyl derivatives useful as calcium channel modulators and a preparation method of the same. Also disclosed is a method for the treatment of diseases by administering the above compounds based on their inhibitory activity against calcium channel.

Imidazolylalkylcarbonyl derivatives as calcium channel modulators and preparation method thereof

Provided are a novel 1,6-disubstituted-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-7-one compound, a pharmaceutically acceptable salt compound thereof, a method for preparing the compound, and an anticancer pharmaceutical composition including the compound as an effective ingredient.

1,6-disubstituted-3-amino-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-C]pyridin-7-one compounds and preparation thereof

The present invention relates to a novel piperazinyl-propyl-pyrazole derivative, a method of its preparation and a pharmaceutically acceptable composition comprising the same. The novel piperazinyl-propyl-pyrazole derivative of the present invention has superior selective affinity for dopamine Dreceptor, can effectively inhibit psychotic behavior (cage climbing) induced by apomorphine, and has relatively low adverse effects in mouse rotarod test. Therefore, it can be developed as a therapeutic agent for the treatment and prevention of central nervous system (CNS) disorders, in particular, schizophrenia, attention deficit hyperactivity disorder, depression, stress diseases, panic disorder, phobia, obsessive-compulsive disorder, posttraumatic stress disorder, cognitive disorder, Alzheimer's disease, Parkinson's disease, anxiety, paraphrenia, mania, seizure disorder, personality disorder, migraine, drug addiction, alcohol addiction, obesity, eating disorder, and sleeping disorder.

Piperazinyl-propyl-pyrazole derivatives as dopamine D4 receptor antagonists, and pharmaceutical compositions containing the same

The present invention relates to pyrazolylmethylamine-piperazine derivatives and their pharmaceutically acceptable salts effective as calcium channel modulators and a method of manufacturing the same. The present invention also relates to the medicinal use of the above compounds as therapeutic treatment of diseases due to their effect as calcium channel modulators.

Pyrazolylmethylamine compounds as calcium channel modulators and preparation method thereof

The present invention relates to a novel piperazinyl-propyl-pyrazole derivative, a method of its preparation and a pharmaceutically acceptable composition comprising the same. The novel piperazinyl-propyl-pyrazole derivative of the present invention has superior selective affinity for dopamine D4 receptor, can effectively inhibit psychotic behavior (cage climbing) induced by apomorphine, and has relatively low adverse effects in mouse rotarod test. Therefore, it can be developed as a therapeutic agent for the treatment and prevention of central nervous system (CNS) disorders, in particular, schizophrenia, attention deficit hyperactivity disorder, depression, stress diseases, panic disorder, phobia, obsessive-compulsive disorder, posttraumatic stress disorder, cognitive disorder, Alzheimer's disease, Parkinson's disease, anxiety, paraphrenia, mania, seizure disorder, personality disorder, migraine, drug addiction, alcohol addiction, obesity, eating disorder, and sleeping disorder.

The present invention relates to a novel medicinal use of pyrazolopyrimidine compounds having superior effect as serotonin 5-HTreceptor ligand thus being useful for the prevention and treatment of central nervous system (CNS) diseases. Accordingly, the pharmaceutical composition comprising pyrazolopyrimidine compounds and their pharmaceutically acceptable salts as active ingredients are useful for the prevention and treatment of serotonin 5-HT-related central nervous system diseases such as obesity, depression, anxiety and withdrawal symptoms due to drug abuse.

Pyrazolopyrimidine derivatives having biological activity on serotonin receptor 5-HT2c

Compounds and compositions are provided for treatment, prevention, or amelioration of a variety of medical disorders associated with viral infections and/or cell proliferation. The compounds provided herein are 5-phosphono-pent-2-en-1-yl nucleosides and esters thereof.

Phosphono-pent-2-en-1-yl nucleosides and analogs

Disclosed are isoindolinone derivatives, represented by Chemical Formula 1, having inhibitory activity against T-type calcium channels, pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient. 

Isoindolinone derivatives having inhibitory activity against T-type calcium channel and method for preparation thereof

Growing community of inventors

Seoul, South Korea

Hyunah Choo